ATE309991T1 - Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs - Google Patents

Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs

Info

Publication number
ATE309991T1
ATE309991T1 AT98922070T AT98922070T ATE309991T1 AT E309991 T1 ATE309991 T1 AT E309991T1 AT 98922070 T AT98922070 T AT 98922070T AT 98922070 T AT98922070 T AT 98922070T AT E309991 T1 ATE309991 T1 AT E309991T1
Authority
AT
Austria
Prior art keywords
cancer
cdk
inhibitors
treatment
dependent kinase
Prior art date
Application number
AT98922070T
Other languages
English (en)
Inventor
Michael J Kelley
Kazuhiko Nakagawa
Barry Roy Dent
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE309991T1 publication Critical patent/ATE309991T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT98922070T 1997-04-28 1998-04-28 Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs ATE309991T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4425697P 1997-04-28 1997-04-28
PCT/US1998/008602 WO1998049146A2 (en) 1997-04-28 1998-04-28 Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer

Publications (1)

Publication Number Publication Date
ATE309991T1 true ATE309991T1 (de) 2005-12-15

Family

ID=21931359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98922070T ATE309991T1 (de) 1997-04-28 1998-04-28 Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs

Country Status (8)

Country Link
US (1) US6630464B1 (de)
EP (1) EP0977738B1 (de)
JP (1) JP2002506427A (de)
AT (1) ATE309991T1 (de)
AU (1) AU736979B2 (de)
CA (1) CA2288154A1 (de)
DE (1) DE69832374D1 (de)
WO (1) WO1998049146A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
MXPA03005870A (es) * 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
DE60325579D1 (de) * 2002-03-25 2009-02-12 Theryte Ltd Krebsbehandlung
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3090783A (en) * 1962-06-12 1963-05-21 Olin Mathieson Dihydrobenzothiadiazines
DE3331459A1 (de) * 1982-08-31 1984-03-01 Martin Dr.med. 6900 Heidelberg Berger Zubereitung zur tumorbehandlung mit einem gehalt an diazoxid und dessen verwendung
FR2676737A1 (fr) * 1991-05-23 1992-11-27 Groupe Enseignement Rech Chim Dimeres 9-thioacridinoniques pontes par une chaine heteroatomique incluant un noyau biphenyle.
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use

Also Published As

Publication number Publication date
CA2288154A1 (en) 1998-11-05
WO1998049146A3 (en) 1999-08-12
AU736979B2 (en) 2001-08-09
EP0977738A2 (de) 2000-02-09
US6630464B1 (en) 2003-10-07
AU7469898A (en) 1998-11-24
EP0977738B1 (de) 2005-11-16
WO1998049146A2 (en) 1998-11-05
JP2002506427A (ja) 2002-02-26
DE69832374D1 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
Gelbert et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
ATE265456T1 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
ATE309223T1 (de) Cyclin-abhängige kinase inhibitoren
Khalil et al. Rho GTPases in primary brain tumor malignancy and invasion
BRPI0616987A2 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
AP2001002341A0 (en) Diaminothiazoles and their use for inhibiting protein kinases.
BR0314001A (pt) Pirazolopirimidinas como inibidores de cinase dependente de ciclina
BRPI0507644B8 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ATE470668T1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs
AP1486A (en) Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use.
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
NZ503828A (en) Aminothiazole inhibitors of cyclin dependent kinases
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
MY137888A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE378321T1 (de) Pyrazolopyrimidine
BG104938A (bg) Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства
ATE365163T1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties